Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$8.30 USD
-0.11 (-1.31%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $8.40 +0.10 (1.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Tango Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 37 | 25 | 37 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 37 | 25 | 37 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 151 | 136 | 95 | 0 | 0 |
Income After Depreciation & Amortization | -114 | -111 | -58 | 0 | 0 |
Non-Operating Income | 13 | 3 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -102 | -108 | -58 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -102 | -108 | -58 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -102 | -108 | -58 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -115 | -109 | -57 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 2 | 1 | 0 | NA |
Income After Depreciation & Amortization | -114 | -111 | -58 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 94.57 | 87.82 | 62.11 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.08 | -1.23 | -0.94 | NA | NA |
Diluted Net EPS (GAAP) | -1.08 | -1.23 | -0.94 | -0.04 | NA |
Fiscal Year end for Tango Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 19.88 | 6.47 | 5.43 | 10.73 | 14.60 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 19.88 | 6.47 | 5.43 | 10.73 | 14.60 |
SG&A, R&D, and Dept/Amort Expenses | 49.42 | 48.73 | 40.45 | 36.36 | 37.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | -29.54 | -42.26 | -35.02 | -25.63 | -23.24 |
Non-Operating Income | 4.07 | 4.38 | 4.30 | 3.39 | 2.60 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -25.49 | -37.87 | -30.72 | -22.24 | -20.65 |
Income Taxes | 0.07 | 0.04 | 0.05 | 0.02 | 0.06 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -25.55 | -37.91 | -30.76 | -22.26 | -20.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -25.55 | -37.91 | -30.76 | -22.26 | -20.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 108.31 | 108.17 | 97.22 | 97.03 | 88.36 |
Diluted EPS Before Non-Recurring Items | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
Diluted Net EPS (GAAP) | -0.24 | -0.35 | -0.30 | -0.23 | -0.23 |